Saturday, 31 October 2026European Markets

VOPAK Stock Was Up By 11.16% Today

Loading stream...

(VIANEWS) - The Market ended the session with VOPAK (VPK.AS) rising 11.16% to €32.88 on Wednesday while AEX-Index jumped 0.12% to €843.67.

About VOPAK

Koninklijke Vopak N.V., an independent tank storage company, stores and handles liquid chemicals, gases, and oil products worldwide. The company owns and operates terminals, including storage tanks, jetties, truck and rail loading stations and pipelines, as well as provide access to road, rail, and pipeline networks. It operates 78 terminals in 23 countries with a storage capacity of 36.6 million cbm. The company was founded in 1616 and is headquartered in Rotterdam, the Netherlands.

Earnings Per Share

As for profitability, VOPAK has a trailing twelve months EPS of €3.13.

PE Ratio

VOPAK has a trailing twelve months price to earnings ratio of 10.5. Meaning, the purchaser of the share is investing €10.5 for every euro of annual earnings.

Volatility

VOPAK's last week, last month's, and last quarter's current intraday variation average was a positive 0.80%, a negative 0.12%, and a positive 0.85%.

VOPAK's highest amplitude of average volatility was 1.03% (last week), 1.01% (last month), and 0.85% (last quarter).

More news about VOPAK (VPK.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com